COMP <GO>
MDLN vs WST // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Medline Inc. (NASDAQ) VS. West Pharmaceutical Services Inc. (NYSE) • 15-METRIC TALLY: MDLN 6
— WST 6
■ METRIC PARITY
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
options-implied-move
—
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. WST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | WST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 35.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 17.90% | -9.70 | WST | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 34.7x | -14.40 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 1.60% | +1.48 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 19.00% | -11.20 | WST | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 16.10% | +51.90 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.30% | +5.20 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.21% | -0.21 | WST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 19.06 | -16.56 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | WST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 77.0 | -46.10 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.08 | +0.03 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 55.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $29.32B | $12.75B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | WST REV | MDLN GROSS % | WST GROSS % | MDLN FCF | WST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $3.07B | 26.4% | 35.9% | $1.30B | $468.9M |
| FY 2024 | $25.51B | $2.89B | 27.3% | 34.5% | $1.42B | $276.4M |
| FY 2023 | $23.23B | $2.95B | — | — | $639.6M | $643.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
WST // BETA 1.08